anti-melanoma mab fragments
Various (V09)Various (V09) compound in Pyxis Oncology's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
pharma · Advanced Solid Tumors · Solid Tumor · PYXS
Pyxis Oncology
Pyxis Oncology drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boston, USA HQ
2019 Founded
71 Employees
Public company Type
PYXS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2019
- Employees
- 71
- Programs
- 8
- Drugs
- 6
- Patents
- 3
Pyxis Oncology pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Pyxis Oncology drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Pyxis Oncology in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Pyxis Oncology in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Pyxis Oncology in public FDA and regional records.